Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority ProgramsGlobeNewsWire • 11/05/24
Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual MeetingGlobeNewsWire • 10/29/24
Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report?Zacks Investment Research • 09/05/24
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial ResultsGlobeNewsWire • 08/06/24
Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?Zacks Investment Research • 07/26/24
Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40InvestorPlace • 07/24/24
Beam Therapeutics (BEAM) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 07/09/24
Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)GlobeNewsWire • 06/26/24
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell DiseaseGlobeNewsWire • 06/14/24
Why Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report?Zacks Investment Research • 06/06/24
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid CongressGlobeNewsWire • 05/14/24